No Data
Zentalis Pharmaceuticals Insiders Still US$137k Away From Original Investment Value
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9
Stifel analyst Bradley Canino maintains $Zentalis Pharmaceuticals(ZNTL.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 45.3%
Stifel Nicolaus Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
No Data
No Data